21 June | Webinar: Evaluation and Implementation of NGS Liquid Biopsy Assays
Date: June 21, 2018
Time: 19:00 European Summer Time (Amsterdam, GMT+02:00)
This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.
Interest in liquid biopsy has escalated in recent years due to the minimally invasive sampling method, potential to overcome the challenges of tumor heterogeneity, and the potential for longitudinal monitoring of tumor burden through serial sampling. Furthermore, the growing adoption of NGS allows more labs to perform NGS liquid biopsy tests in house.
In this webinar, Dr. Tomasz Zemojtel of the Berlin Institute of Health will discuss how his lab implemented Roche’s AVENIO ctDNA Analysis Kits for in-house clinical research testing.
He will discuss:
· Utility and flexibility of liquid biopsy assays for various research applications
· Specific parts of the liquid biopsy workflow that are critical for achieving high technical performance and accurate results, such as molecular barcoding and hybrid capture technology
· Implementation strategy for liquid biopsy assays using artificial plasma samples
· Data analysis and interpretation
Lastly, Dr. Zemojtel will discuss the data obtained with the AVENIO assay workflow from clinical research subjects with ovarian cancer.
BIH Genomics Core Platform
Tomasz Zemojtel, Head of BIH Genomics Platform, joined BIH in 2017 when he was appointed to build the BIH Genomics Core Unit. This facility combines solid technical wet lab expertise with strong bioinformatics skills in implementing state of the art genomics services. Tomasz’s primary role is in interfacing with and providing end-to-end molecular diagnostic solutions to clinicians. Prior to BIH, Dr. Zemojtel began translating genomics-based tools into clinical diagnostics during his work with Martin Vingron and Hilger Ropers from 2004 – 2012, at the Max Planck Institute for Molecular Genetics. From 2013 – 2017 he established and led a molecular genetics diagnostic laboratory at Labor Berlin, where he implemented a wide-range of NGS-based diagnostic tests, and designed silico-based clinical workflows (e.g. Zemojtel et al. 2014 Sci.Transl.Med.), translating them into the clinical setting of the University Clinics Charite. Tomasz holds a PhD in Biochemistry from the University of Heidelberg in Germany, and a M.Sc. in Computer Science from the Gdansk University of Technology in Poland.